Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria reduction 1 Iptacopan is an investigational, first-in-class, oral factor B inhibitor targeting the alternative pathway of the complement system 2–4 IgAN is a complement-mediated kidney disease, affects mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide 5–9 Novartis plans to review interim results with FDA to enable a potential regulatory submission for accelerated approval; study continues with final readout (24 months) in 2025 4 APPLAUSE-IgAN is the third positive Phase III trial for iptacopan and development program is ongoing across five indications; regulatory review is underway for paroxysmal nocturnal hemoglobinuria (PNH) in the US and EU 10,11 Basel, October 2, 2023 — Novartis today announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months1.

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Basel, September 29th, 2023 — Novartis today announced that it has completed its divestment of ‘front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, consisting of 1.75 billion in upfront cash, plus potential additional milestone payments.

Novartis completes divestment of ‘front of eye' ophthalmology assets

British American Tobacco

Diageo

SAP SE

Sanofi

TotalEnergies SE

It was nice while it lasted, but the AI-driven stock market rally is rapidly running out of gas.

The US Stock Market Could Crack in October: 6 ‘Strong Buy' European Dividend Aristocrats to Buy Now

Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.

Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar

Novartis' core EPS payout ratio is poised to come in at around 51% in 2023. The Swiss drugmaker grew at a solid clip in the first half of this year. The company enjoys an AA- credit rating from ratings agency S&P.

Novartis: Buy This Dividend Aristocrat For Consistent Income

Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.

Novartis (NVS) Lutathera Meets Primary Goal in Phase III Study

Novo Nordisk

AstraZeneca

Morgan Stanley (NYSE:MS) expects the EU biopharma sector to offer a safe haven from weakening growth/higher real yields. “Whilst we continue to favour growth/innovation narratives in biopharma over the long-term, we expect investors to reward earnings upgrade stories - Novo Nordisk, Novartis, AstraZeneca - in the near-term,” it said.

Morgan Stanley sees biopharma sector as a 'safe haven'

Biogen

bluebird bio

BioMarin Pharmaceutical

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Regeneron Pharmaceuticals

Solid Biosciences

Sarepta Therapeutics

It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASDAQ: SRPT, which are developing gene therapies. ‘

Are Gene Therapy Stocks The Market's Next Big Winners?

Novartis on Monday confirmed its plans for a 100% spin-off of the Sandoz business on Oct. 4 after shareholders gave their approval earlier this month.

Novartis confirms Sandoz spin-off for October 4, 2023

Basel, September 25, 2023 — Today, Novartis announced the Phase III NETTER-2 trial with Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) met its primary endpoint. First line treatment with Lutathera in combination with long-acting octreotide demonstrated a significant improvement in progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor (SSTR)-positive, Grade 2 and 3, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus high-dose long-acting octreotide alone1,2. No new or unexpected safety findings were observed in the study and data are consistent with the already well-established safety profile of Lutathera1 - 4.

Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Basel, September 25, 2023 — Novartis today confirmed plans for the 100% Spin-off of the Sandoz business, with trading of new Sandoz Group AG shares and ADRs (American Depositary Receipts) to commence on October 4, 2023.

Novartis confirms Sandoz Spin-off for October 4, 2023

BeiGene

Bristol-Myers

Kezar Life Sciences Inc

Ocular Therapeutix

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. Once again, a big pharma has returned partnership rights for BeiGene's anti-PD-1 candidate to the China company. Shanghai AffaMed Therapeutics has treated the first patient in a China Phase III registrational study that will test the efficacy and safety of Dextenza as a therapy for ocular inflammation and pain following ophthalmic surgery.

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement

BeiGene said on Tuesday it would regain rights to develop and manufacture its cancer drug after a deal termination with Novartis.

BeiGene regains rights for cancer drug after Novartis deal termination

Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.

Novartis' (NVS) Shareholders Approve Sandoz Separation

Novartis (NYSE: NVS ) stock is rising higher on Friday after the company announced approval for the spinoff of its generic drugs business Sandoz. Novartis conducted a shareholder vote on Friday seeking approval for the spinoff of Sandoz.

NVS Stock Alert: Novartis Shareholders Approve Sandoz Spinoff

Basel, September 15, 2023 — At an Extraordinary General Meeting held today, Novartis shareholders approved the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis.

Novartis shareholders approve the proposed 100% Spin-off of Sandoz

Novartis shareholders on Friday voted in favour of spinning off the Swiss company's generic-drugs business Sandoz, with investors holding 99.7% of the represented capital supporting the proposal.

Novartis shareholders vote in favour of Sandoz spin-off

Novartis (NVS) announces an agreement with Samsung Bioepis for exclusive rights to commercialize the biosimilar of Stelara in Europe and North America. The company discontinues the development of GT005 in geographic atrophy.

Novartis' (NVS) Sandoz Gets Rights for Stelara Biosimilar

Company Contact:Novartis Pharmaceuticals Corporation1-888-669-6682 EAST HANOVER, N.J. , Sept. 11, 2023 /PRNewswire/ -- Novartis is conducting a voluntary nationwide recall at the consumer level of one lot of its Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL in the US due to crystal formation observed in some bottles, which could potentially result in incorrect dosing.

Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

British healthcare investment firm Syncona said on Monday Novartis has stopped the development of experimental eye treatment, GT005, which would result in payments write-off of 54.5 million pounds ($68.23 million) for Gyroscope Holdings Limited.

UK's Syncona writes off 54.5 mln stg after Novartis ends Gyroscope's therapy

Novartis has appointed AbbVie executive Patrick Horber to its executive committee, the Swiss pharmaceuticals maker said on Wednesday, after Chief Commercial Officer Marie-France Tschudin stepped down.

Novartis names new board member after international boss steps down

Basel, September 06, 2023 — Novartis today announced that Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, has decided to leave the company and will step down from the Executive Committee of Novartis (ECN), effective September 15, after nearly seven years of commercial leadership at Novartis. Patrick Horber, M.D., currently Senior Vice President and President, Immunology at AbbVie has been appointed as President, International, effective later this year, reporting to Vas Narasimhan, M.D., CEO of Novartis. Dr. Horber will become a member of the ECN. Mukul Mehta, Chief Financial Officer, International, will lead the unit ad-interim until Dr. Horber assumes the role.

Novartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of Novartis

Novartis' biosimilar candidate to Eylea has proven just as safe and effective. The medicine could generate $500 million in annual sales for the Swiss drugmaker.

Could This Biosimilar Drug Be Novartis' Next Blockbuster?

Swiss drugmaker Novartis on Friday said it had sued the U.S. government in an attempt to halt the Medicare drug-price negotiation program, which includes its top-selling heart-failure medicine Entresto.

Novartis sues US government over Medicare drug price regulation

Astellas Pharma Inc

Amgen

Horizon Pharma

Johnson & Johnson

Eli Lilly

Merck

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen Inc. NASDAQ: AMGN were trading normally following news that their drugs would be subject to next year's Medicare price negotiations.

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?

News for Novartis Stock (NVS)